Pharmacological characterisation of a new oral GH secretagogue, NN703

European Journal of Endocrinology

Volumn 141, Issue 2, 1999, Pages 180-189

  Hansen, B Sehested ^a   Raun, K ^a   Nielsen, K Kramer ^a   Johansen, P Bygballe ^a   Hansen, T Kruse ^a   Peschke, B ^a   Lau, J ^a   Andersen, P Høngaard ^a   Ankersen, M ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; IBUTAMOREN; TABIMORELIN; TRIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; GROWTH HORMONE RELEASE; HYPOPHYSIS CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DIPEPTIDES; DOGS; GROWTH HORMONE; HUMANS; MALE; PITUITARY GLAND; RATS; RATS, SPRAGUE-DAWLEY; SWINE; WEIGHT GAIN;

EID: 0032779234     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410180     Document Type: Article

References (38)

1. Bowers CY, Chang J, Momany F & Folkers K. Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In Molecular Endocrinology, pp 287-292. Ed I Maclntyre. Amsterdam: Elsevier/North Holland, 1977.
2. Hansen BS & Raun K. GH secretagogues - potency and efficacy are model dependent. 10th International Congress of Endocrinology, Abstract P1-583, 1996.
3. 2 in conscious dogs. Life Sciences 1991 48 2283-2288.
4. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY & Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. Journal of Clinical Endocrinology and Metabolism 1993 77 1641-1647.
5. Chapman IM, Bach MA, Vancauter E, Farmer M, Krupa D, Taylor AM et al. Stimulation of the growth-hormone (GH)-insulin-like growth-factor-I axis by daily oral-administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism 1996 81 4249-4257.
6. Howard AD, Feighner SD, Cully D.F, Arena JP, Liberator PA, Rosenblum CI et al. A receptor in pituitary and hypothalamus that functions in growth-hormone release. Science 1996 273 974-977.
7. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJS et al. Distribution of messenger-RNA encoding the growth-hormone secretagogue receptor in brain and peripheral tissues. Molecular Brain Research 1997 48 23-29.
8. Copinschi G, Leproult R, Vanonderbergen A, Gaufriez A, Cole KY, Schilling LM et al. Prolonged oral treatment with MK-677, a novel growth-hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997 66 278-286.
9. Locke W, Kirgis HD, Bowers CY & Abdo AA. Intracerebroventricular growth-hormone-releasing-peptide-6 stimulates eating without affecting plasma growth hormone response in rats. Life Sciences 1995 56 1347-1352.
10. Friesbo RM, Murck H, Maier P, Schier T, Holsboer F & Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol in normal man. Neuroendocrinology 1995 61 584-589.
11. Bowers CY, Momany F, Reynolds GA, Hong A & Newlander K. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984 114 1537-1545.
12. Momany FA, Bowers CY, Renolds GA, Hong A & Newlander K. Conformational energy studies and in vitro and in vivo activity data on growth hormone releasing peptides. Endocrinology 1984 114 1531-1536.
13. Deghenghi R, Bontignon F, Luoni M, Grille R, Guidi M & Locatteli V. Small peptides as potent releasers of growth hormone. Journal of Pediatric Endocrinology and Metabolism 1995 8 311-313.
14. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK et al. A new series of highly potent growth hormone releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry 1998 41 3699-3704.
15. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M & Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998 139 552-561.
16. Cheng K, Chan WW, Butler B, Wei L & Smith RG. A novel nonpeptidyl growth hormone secretagogue. Hormone Research 1993 40 109-115.
17. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DBR et al. Design and biological activities of 1-163, 191 (MK-0677) - a potent, orally-active growth-hormone secretagogue. Proceedings of the National Academy of Sciences of the USA 1995 92 7001-7005.
18. Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J et al. A peptidomimetic strategy leading to a novel class of orally active growth hormone secretagogues. Journal of Medicinal Chemistry 1998 41 3705-3714.
19. 50) of an enzymatic reaction. Biochemical Pharmacology 1973 22 3099-3108.
20. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 1989 124 2791-2798.
21. Robberecht P, Coy DH, Waelbroeck M, Heiman ML, de Neef P, Camus JC & Christophe J. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF). Endocrinology 1985 117 1759-1764.
22. Rasmussen MH, Søgaard B, Ynddal L, Groes L, Helmgaard L & Nordholm L. Ipamorelin - A novel very potent growth hormone secretagogue. Growth Hormone and IGF Research 1998 8 332 (Abstract P-11).
23. Muccioli G, Ghe C, Ghigo MC, Papotti M, Arvat E, Boghen MF et al. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. Journal of Endocrinology 1998 157 99-106.
24. Ong H, McNicoll N, Escher E, Collu R, Deghenghi R, Locatelli V et al. Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity-labeling. Endocrinology 1998 139 432-435.
25. McDowell RS, Elias, KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS et al. Novel growth hormone secretagogues: minimal bioactive conformation, characterization, and efficacy. Proceedings of the National Academy of Sciences of the USA 1995 92 11165-11169.
26. Hickey G, Drisko J, Faidley T, Chang C, Anderson LL, Nicolich S et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. Journal of Endocrinology 1996 148 371-380.
27. Chang CH, Rickes EL, Marsilio F, McGurie L, Cosgrove S, Taylor J et al. Activity of a novel nonpeptidyl growth hormone secretagogue, L-700,653, in swine. Endocrinology 1995 136 1065-1071.
28. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D et al. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. Endocrinology 1994 143 399-406.
29. Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C & Casanueva F. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clinical Endocrinology 1994 41 649-654.
30. Arvat E, Divito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R et al. Effects of GHRP-2 and hexarelin, 2 synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man -comparison with the effects of GHRH, TRH and HCRH. Peptides 1997 18 885-891.
31. Clark RG, Thomas GB, Mortensen DL, Won WB, Ma YH, Tomlinson EE et al. Growth-hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 1997 138 4316-4323.
32. Hickey G, Jacks T, Judith F, Taylor J, Schoen WR, Krupa D et al. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth-hormone secretagogue, in beagles. Endocrinology 1994 134 695-701.
33. Copinschi G, Vanonderbergen A, Lhermitebaleriaux M, Mendel CM, Caufriez A, Leproult R et al. Effects of a 7-day treatment with a novel, orally-active, growth-hormone (GH) secretagogue, MK-677, on 24-h GH profiles, insulin-like growth-factor-I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism 1996 81 2776-2782.
34. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R et al. Adrenocorticotropin-releasing and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushings syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 2439-2444.
35. Johansen BP, Nowak J, Skjærbæk C, Flyvbjerg A, Andreassen TT, Wilken M & Ørskov H, Ipamorelin, a new growth hormone releasing peptide, induces longitudinal bone growth in rats. Growth Hormone and IGF Research 1999 9 106-113.
36. Casanueva FF & Dieguez. Growth hormone secretagogues: Physiological role and clinical utility. Trends in Endocrinology and Metabolism 1999 10 30-38.
37. Pan LC, Carpino PA, Lefker BA, Pirie CM, Chidsey-Frink K, Ng OC et al. CP-424, 391: A novel orally active growth hormone secretagogue in rats and dogs. Proceedings of the Endocrine Society 1998, Abstract P2-190.
38. Clark RG, Thomas GB, Mortensen DL, Won WB, Ma YH, Tomlinson EE et al. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 1997 138 4316-4323.